Indeed, randomized clinical trials have been performed assessing perioperative use of nsBBs alone, in breast and ovarian cancer, and in combination with cyclooxygenase 2 inhibition in colorectal cancer.20,36,37. The gene discussed is PTGS2; the disease is ovarian cancer.